Loading data
PMNNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development expense | 33.38 m USD | 10.64 m USD | 7.88 m USD | 16.09 m USD | 4.63 m USD |
| Operating profit | -40.17 m USD | -16.83 m USD | -14.26 m USD | -23.38 m USD | -8.29 m USD |
| Income tax expense | — | 0 USD | 0 USD | 0 USD | — |
| Net income (reported basis) | -39.72 m USD | 2.78 m USD | -13.21 m USD | -18.06 m USD | -9.79 m USD |
| Net income attributable to common shareholders | -39.72 m USD | 2.78 m USD | -13.21 m USD | 18.06 m USD | 9.79 m USD |
| Basic earnings per share | -22.61 USD/share | 2.68 USD/share | -1.07 USD/share | -2.41 USD/share | -1.69 USD/share |
| Diluted earnings per share | -22.61 USD/share | 2.63 USD/share | -1.07 USD/share | -2.41 USD/share | -1.69 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.